352 related articles for article (PubMed ID: 16461865)
1. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
Comer SD; Sullivan MA; Yu E; Rothenberg JL; Kleber HD; Kampman K; Dackis C; O'Brien CP
Arch Gen Psychiatry; 2006 Feb; 63(2):210-8. PubMed ID: 16461865
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
[TBL] [Abstract][Full Text] [Related]
3. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.
Grabowski J; Rhoades H; Stotts A; Cowan K; Kopecky C; Dougherty A; Moeller FG; Hassan S; Schmitz J
Neuropsychopharmacology; 2004 May; 29(5):969-81. PubMed ID: 15039761
[TBL] [Abstract][Full Text] [Related]
4. Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.
Strang J; Kelleher M; Mayet S; Day E; Hellier J; Byford S; Murphy C; McLennan B; Shearer J; Ryan E; Marsden J
Health Technol Assess; 2019 Jan; 23(3):1-72. PubMed ID: 30702059
[TBL] [Abstract][Full Text] [Related]
5. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone and buprenorphine combination in the treatment of opioid dependence.
Gerra G; Fantoma A; Zaimovic A
J Psychopharmacol; 2006 Nov; 20(6):806-14. PubMed ID: 16401652
[TBL] [Abstract][Full Text] [Related]
7. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.
Jarvis BP; Holtyn AF; DeFulio A; Koffarnus MN; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Drug Alcohol Depend; 2019 Apr; 197():220-227. PubMed ID: 30852374
[TBL] [Abstract][Full Text] [Related]
8. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.
Everly JJ; DeFulio A; Koffarnus MN; Leoutsakos JM; Donlin WD; Aklin WM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Addiction; 2011 Jul; 106(7):1309-18. PubMed ID: 21320227
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
10. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.
Comer SD; Collins ED; Kleber HD; Nuwayser ES; Kerrigan JH; Fischman MW
Psychopharmacology (Berl); 2002 Feb; 159(4):351-60. PubMed ID: 11823887
[TBL] [Abstract][Full Text] [Related]
11. Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.
Runarsdottir V; Hansdottir I; Tyrfingsson T; Einarsson M; Dugosh K; Royer-Malvestuto C; Pettinati H; Khalsa J; Woody GE
J Addict Med; 2017; 11(3):197-204. PubMed ID: 28379861
[TBL] [Abstract][Full Text] [Related]
12. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
13. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
[TBL] [Abstract][Full Text] [Related]
14. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
[TBL] [Abstract][Full Text] [Related]
16. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.
Sullivan MA; Vosburg SK; Comer SD
Psychopharmacology (Berl); 2006 Nov; 189(1):37-46. PubMed ID: 16972105
[TBL] [Abstract][Full Text] [Related]
17. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription.
Dürsteler-MacFarland KM; Farronato NS; Strasser J; Boss J; Kuntze MF; Petitjean SA; Bürki C; Wiesbeck GA
J Clin Psychopharmacol; 2013 Feb; 33(1):104-8. PubMed ID: 23277248
[TBL] [Abstract][Full Text] [Related]
19. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
[TBL] [Abstract][Full Text] [Related]
20. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.
Poling J; Oliveto A; Petry N; Sofuoglu M; Gonsai K; Gonzalez G; Martell B; Kosten TR
Arch Gen Psychiatry; 2006 Feb; 63(2):219-28. PubMed ID: 16461866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
